Cancer Antibody Drug Conjugates Market - Global Outlook and Forecast 2022-2028
Report Code: KNJ1156144 No. of Pages: 119 Category: Pharmaceuticals and Healthcare
Publisher: Date of Publish:
Publisher: Date of Publish:
This report contains market size and forecasts of Cancer Antibody Drug Conjugates in global, including the following market information:
Global Cancer Antibody Drug Conjugates Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Cancer Antibody Drug Conjugates Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Cancer Antibody Drug Conjugates companies in 2021 (%)
The global Cancer Antibody Drug Conjugates market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
First & Second Generation ADCs Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Cancer Antibody Drug Conjugates include Novartis, Merck, Roche, AbbVie, UCB, Bristol-Myers Squibb, Stem CentRx, Biogen Idec and Nordic Nanovector, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cancer Antibody Drug Conjugates manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cancer Antibody Drug Conjugates Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Cancer Antibody Drug Conjugates Market Segment Percentages, by Type, 2021 (%)
First & Second Generation ADCs
Third Generation ADCs
Global Cancer Antibody Drug Conjugates Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Cancer Antibody Drug Conjugates Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Cancer Antibody Drug Conjugates Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Cancer Antibody Drug Conjugates Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cancer Antibody Drug Conjugates revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Cancer Antibody Drug Conjugates revenues share in global market, 2021 (%)
Key companies Cancer Antibody Drug Conjugates sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Cancer Antibody Drug Conjugates sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Merck
Roche
AbbVie
UCB
Bristol-Myers Squibb
Stem CentRx
Biogen Idec
Nordic Nanovector
Millennium
Biotest AG
PDL BioPharma
Progenics Pharmaceuticals
Seattle Genetics
Viventia Biotechnologies
AbGenomics Corporation
Helix BioPharma
1 Introduction to Research & Analysis Reports
1.1 Cancer Antibody Drug Conjugates Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Cancer Antibody Drug Conjugates Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Cancer Antibody Drug Conjugates Overall Market Size
2.1 Global Cancer Antibody Drug Conjugates Market Size: 2021 VS 2028
2.2 Global Cancer Antibody Drug Conjugates Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Cancer Antibody Drug Conjugates Sales: 2017-2028
3 Company Landscape
3.1 Top Cancer Antibody Drug Conjugates Players in Global Market
3.2 Top Global Cancer Antibody Drug Conjugates Companies Ranked by Revenue
3.3 Global Cancer Antibody Drug Conjugates Revenue by Companies
3.4 Global Cancer Antibody Drug Conjugates Sales by Companies
3.5 Global Cancer Antibody Drug Conjugates Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Cancer Antibody Drug Conjugates Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Cancer Antibody Drug Conjugates Product Type
3.8 Tier 1, Tier 2 and Tier 3 Cancer Antibody Drug Conjugates Players in Global Market
3.8.1 List of Global Tier 1 Cancer Antibody Drug Conjugates Companies
3.8.2 List of Global Tier 2 and Tier 3 Cancer Antibody Drug Conjugates Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Cancer Antibody Drug Conjugates Market Size Markets, 2021 & 2028
4.1.2 First & Second Generation ADCs
4.1.3 Third Generation ADCs
4.2 By Type - Global Cancer Antibody Drug Conjugates Revenue & Forecasts
4.2.1 By Type - Global Cancer Antibody Drug Conjugates Revenue, 2017-2022
4.2.2 By Type - Global Cancer Antibody Drug Conjugates Revenue, 2023-2028
4.2.3 By Type - Global Cancer Antibody Drug Conjugates Revenue Market Share, 2017-2028
4.3 By Type - Global Cancer Antibody Drug Conjugates Sales & Forecasts
4.3.1 By Type - Global Cancer Antibody Drug Conjugates Sales, 2017-2022
4.3.2 By Type - Global Cancer Antibody Drug Conjugates Sales, 2023-2028
4.3.3 By Type - Global Cancer Antibody Drug Conjugates Sales Market Share, 2017-2028
4.4 By Type - Global Cancer Antibody Drug Conjugates Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Cancer Antibody Drug Conjugates Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Cancer Antibody Drug Conjugates Revenue & Forecasts
5.2.1 By Application - Global Cancer Antibody Drug Conjugates Revenue, 2017-2022
5.2.2 By Application - Global Cancer Antibody Drug Conjugates Revenue, 2023-2028
5.2.3 By Application - Global Cancer Antibody Drug Conjugates Revenue Market Share, 2017-2028
5.3 By Application - Global Cancer Antibody Drug Conjugates Sales & Forecasts
5.3.1 By Application - Global Cancer Antibody Drug Conjugates Sales, 2017-2022
5.3.2 By Application - Global Cancer Antibody Drug Conjugates Sales, 2023-2028
5.3.3 By Application - Global Cancer Antibody Drug Conjugates Sales Market Share, 2017-2028
5.4 By Application - Global Cancer Antibody Drug Conjugates Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global Cancer Antibody Drug Conjugates Market Size, 2021 & 2028
6.2 By Region - Global Cancer Antibody Drug Conjugates Revenue & Forecasts
6.2.1 By Region - Global Cancer Antibody Drug Conjugates Revenue, 2017-2022
6.2.2 By Region - Global Cancer Antibody Drug Conjugates Revenue, 2023-2028
6.2.3 By Region - Global Cancer Antibody Drug Conjugates Revenue Market Share, 2017-2028
6.3 By Region - Global Cancer Antibody Drug Conjugates Sales & Forecasts
6.3.1 By Region - Global Cancer Antibody Drug Conjugates Sales, 2017-2022
6.3.2 By Region - Global Cancer Antibody Drug Conjugates Sales, 2023-2028
6.3.3 By Region - Global Cancer Antibody Drug Conjugates Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Cancer Antibody Drug Conjugates Revenue, 2017-2028
6.4.2 By Country - North America Cancer Antibody Drug Conjugates Sales, 2017-2028
6.4.3 US Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.4.4 Canada Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.4.5 Mexico Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Cancer Antibody Drug Conjugates Revenue, 2017-2028
6.5.2 By Country - Europe Cancer Antibody Drug Conjugates Sales, 2017-2028
6.5.3 Germany Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.5.4 France Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.5.5 U.K. Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.5.6 Italy Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.5.7 Russia Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.5.8 Nordic Countries Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.5.9 Benelux Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Cancer Antibody Drug Conjugates Revenue, 2017-2028
6.6.2 By Region - Asia Cancer Antibody Drug Conjugates Sales, 2017-2028
6.6.3 China Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.6.4 Japan Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.6.5 South Korea Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.6.6 Southeast Asia Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.6.7 India Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Cancer Antibody Drug Conjugates Revenue, 2017-2028
6.7.2 By Country - South America Cancer Antibody Drug Conjugates Sales, 2017-2028
6.7.3 Brazil Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.7.4 Argentina Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Cancer Antibody Drug Conjugates Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Cancer Antibody Drug Conjugates Sales, 2017-2028
6.8.3 Turkey Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.8.4 Israel Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.8.5 Saudi Arabia Cancer Antibody Drug Conjugates Market Size, 2017-2028
6.8.6 UAE Cancer Antibody Drug Conjugates Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 Novartis
7.1.1 Novartis Corporate Summary
7.1.2 Novartis Business Overview
7.1.3 Novartis Cancer Antibody Drug Conjugates Major Product Offerings
7.1.4 Novartis Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.1.5 Novartis Key News
7.2 Merck
7.2.1 Merck Corporate Summary
7.2.2 Merck Business Overview
7.2.3 Merck Cancer Antibody Drug Conjugates Major Product Offerings
7.2.4 Merck Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.2.5 Merck Key News
7.3 Roche
7.3.1 Roche Corporate Summary
7.3.2 Roche Business Overview
7.3.3 Roche Cancer Antibody Drug Conjugates Major Product Offerings
7.3.4 Roche Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.3.5 Roche Key News
7.4 AbbVie
7.4.1 AbbVie Corporate Summary
7.4.2 AbbVie Business Overview
7.4.3 AbbVie Cancer Antibody Drug Conjugates Major Product Offerings
7.4.4 AbbVie Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.4.5 AbbVie Key News
7.5 UCB
7.5.1 UCB Corporate Summary
7.5.2 UCB Business Overview
7.5.3 UCB Cancer Antibody Drug Conjugates Major Product Offerings
7.5.4 UCB Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.5.5 UCB Key News
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Corporate Summary
7.6.2 Bristol-Myers Squibb Business Overview
7.6.3 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Major Product Offerings
7.6.4 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.6.5 Bristol-Myers Squibb Key News
7.7 Stem CentRx
7.7.1 Stem CentRx Corporate Summary
7.7.2 Stem CentRx Business Overview
7.7.3 Stem CentRx Cancer Antibody Drug Conjugates Major Product Offerings
7.7.4 Stem CentRx Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.7.5 Stem CentRx Key News
7.8 Biogen Idec
7.8.1 Biogen Idec Corporate Summary
7.8.2 Biogen Idec Business Overview
7.8.3 Biogen Idec Cancer Antibody Drug Conjugates Major Product Offerings
7.8.4 Biogen Idec Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.8.5 Biogen Idec Key News
7.9 Nordic Nanovector
7.9.1 Nordic Nanovector Corporate Summary
7.9.2 Nordic Nanovector Business Overview
7.9.3 Nordic Nanovector Cancer Antibody Drug Conjugates Major Product Offerings
7.9.4 Nordic Nanovector Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.9.5 Nordic Nanovector Key News
7.10 Millennium
7.10.1 Millennium Corporate Summary
7.10.2 Millennium Business Overview
7.10.3 Millennium Cancer Antibody Drug Conjugates Major Product Offerings
7.10.4 Millennium Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.10.5 Millennium Key News
7.11 Biotest AG
7.11.1 Biotest AG Corporate Summary
7.11.2 Biotest AG Cancer Antibody Drug Conjugates Business Overview
7.11.3 Biotest AG Cancer Antibody Drug Conjugates Major Product Offerings
7.11.4 Biotest AG Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.11.5 Biotest AG Key News
7.12 PDL BioPharma
7.12.1 PDL BioPharma Corporate Summary
7.12.2 PDL BioPharma Cancer Antibody Drug Conjugates Business Overview
7.12.3 PDL BioPharma Cancer Antibody Drug Conjugates Major Product Offerings
7.12.4 PDL BioPharma Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.12.5 PDL BioPharma Key News
7.13 Progenics Pharmaceuticals
7.13.1 Progenics Pharmaceuticals Corporate Summary
7.13.2 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Business Overview
7.13.3 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Major Product Offerings
7.13.4 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.13.5 Progenics Pharmaceuticals Key News
7.14 Seattle Genetics
7.14.1 Seattle Genetics Corporate Summary
7.14.2 Seattle Genetics Business Overview
7.14.3 Seattle Genetics Cancer Antibody Drug Conjugates Major Product Offerings
7.14.4 Seattle Genetics Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.14.5 Seattle Genetics Key News
7.15 Viventia Biotechnologies
7.15.1 Viventia Biotechnologies Corporate Summary
7.15.2 Viventia Biotechnologies Business Overview
7.15.3 Viventia Biotechnologies Cancer Antibody Drug Conjugates Major Product Offerings
7.15.4 Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.15.5 Viventia Biotechnologies Key News
7.16 AbGenomics Corporation
7.16.1 AbGenomics Corporation Corporate Summary
7.16.2 AbGenomics Corporation Business Overview
7.16.3 AbGenomics Corporation Cancer Antibody Drug Conjugates Major Product Offerings
7.16.4 AbGenomics Corporation Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.16.5 AbGenomics Corporation Key News
7.17 Helix BioPharma
7.17.1 Helix BioPharma Corporate Summary
7.17.2 Helix BioPharma Business Overview
7.17.3 Helix BioPharma Cancer Antibody Drug Conjugates Major Product Offerings
7.17.4 Helix BioPharma Cancer Antibody Drug Conjugates Sales and Revenue in Global (2017-2022)
7.17.5 Helix BioPharma Key News
8 Global Cancer Antibody Drug Conjugates Production Capacity, Analysis
8.1 Global Cancer Antibody Drug Conjugates Production Capacity, 2017-2028
8.2 Cancer Antibody Drug Conjugates Production Capacity of Key Manufacturers in Global Market
8.3 Global Cancer Antibody Drug Conjugates Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Cancer Antibody Drug Conjugates Supply Chain Analysis
10.1 Cancer Antibody Drug Conjugates Industry Value Chain
10.2 Cancer Antibody Drug Conjugates Upstream Market
10.3 Cancer Antibody Drug Conjugates Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Cancer Antibody Drug Conjugates Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
NEED Help?
If you need any help or guidance, please feel free to call us.
USA : +1 (661) 636 6162
INDIA : +91 9325802062
or
Write us on : sales@kandjmarketresearch.com